URG11 promotes proliferation and induced apoptosis of LNCaP cells

Sun,Chenmin; Zhang,Guangming; Cheng,Shujie; Qian,Haining; Li,Dong; Liu,Min

doi:10.3892/ijmm.2019.4121

URG11 promotes proliferation and induced apoptosis of LNCaP cells

Authors:
- Chenmin Sun
- Guangming Zhang
- Shujie Cheng
- Haining Qian
- Dong Li
- Min Liu
View Affiliations

Affiliations: Department of Anesthesiology, Tongren Hospital Shanghai Jiao Tong University School of Medicine, Shanghai 200336, P.R. China, Department of Urology, Tongren Hospital Shanghai Jiao Tong University School of Medicine, Shanghai 200336, P.R. China
Published online on: March 5, 2019 https://doi.org/10.3892/ijmm.2019.4121
Pages: 2075-2085
Copyright: © Sun et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

von Willebrand factor C and EGF domain‑containing protein (URG11), a cell growth regulator, is involved in the progression of a variety of types of cancer, including prostate cancer (Pca). However, the functions of the URG11 gene in Pca cells require in‑depth investigation. The mRNA and protein levels of URG11 were measured by reverse transcription quantitative polymerase chain reaction (RT‑qPCR) and western blot analysis. Cell Counting kit‑8 (CCK‑8), wound‑healing and Transwell assays were used to detect cell viability, migration and invasion, respectively. Apoptosis and cell cycle analyses were performed using flow cytometry. The mRNA and protein expression levels of epithelial (E)‑cadherin, vimentin, α‑smooth muscle actin (α‑SMA), cyclin D1 and MYC proto‑oncogene protein (c‑Myc) were analyzed by RT‑qPCR and western blot analysis. In the present study, the mRNA and protein levels of URG11 were markedly upregulated in Pca cell lines compared with those in the normal prostate epithelial cell line. With functional experiments, the cell viability, migration and invasion of Pca cells were markedly promoted by URG11 overexpression. The cell cycle was effectively induced by URG11 and apoptosis was inhibited by the overexpression of URG11. Concomitantly, the epithelial marker E‑cadherin was downregulated, and the mesenchymal markers vimentin and α‑SMA were upregulated following URG11 overexpression. By contrast, genetic knockout of URG11 elicited the opposite effects. The present study also identified that the downstream effector genes of the Wnt/β‑catenin signal pathway, cyclin D1 and c‑Myc, were increased following the overexpression of endogenous URG11, which are known to regulate cell proliferation. In addition, the Wnt/β‑catenin inhibitor FH535 ameliorated the promotive effects of URG11 on LNCaP cells viability, migration and invasion, and the Wnt/β‑catenin agonist LiCl reversed the inhibitory effects of siURG11 in LNCaP cells on cell viability, migration and invasion. The present study demonstrated that URG11 served an oncogenic role in the development of Pca cells and provided evidence that URG11 has potential as a novel therapeutic target in Pca.

View Figures

View References

1	Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin. 61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
2	VanderWalde A and Hurria A: Aging and osteoporosis in breast and prostate cancer. CA Cancer J Clin. 61:139–156. 2011. View Article : Google Scholar : PubMed/NCBI
3	Nelson BA, Shappell SB, Chang SS, Wells N, Farnham SB, Smith JA Jr and Cookson MS: Tumour volume is an independent predictor of prostate-specific antigen recurrence in patients undergoing radical prostatectomy for clinically localized prostate cancer. BJU Int. 97:1169–1172. 2006. View Article : Google Scholar : PubMed/NCBI
4	Zhang HF, Wang HL, Xu N, Li SW, Ji GY, Li XM, Pan YZ, Zhang L, Zhao XJ and Gao HW: Mass screening of 12,027 elderly men for prostate carcinoma by measuring serum prostate specific antigen. Chin Med J (Engl). 117:67–70. 2004.
5	Jin Y, Chen Y, Jiang Y and Xu M: Proteome analysis of the silkworm (Bombyx mori. L) colleterial gland during different development stages. Arch Insect Biochem Physiol. 61:42–50. 2006. View Article : Google Scholar
6	Fan R, Li X, Du W, Zou X, Du R, Zhao L, Luo G, Mo P, Xia L, Pan Y, et al: Adenoviral-mediated RNA interference targeting URG11 inhibits growth of human hepatocellular carcinoma. Int J Cancer. 128:2980–2993. 2011. View Article : Google Scholar
7	Lian Z, Liu J, Li L, Li X, Tufan NL, Clayton M, Wu MC, Wang HY, Arbuthnot P, Kew M, et al: Upregulated expression of a unique gene by hepatitis B x antigen promotes hepatocellular growth and tumorigenesis. Neoplasia. 5:229–244. 2003. View Article : Google Scholar : PubMed/NCBI
8	Xie H and Liu J: Increased expression URG11 in hepatocellular carcinoma tissues promotes the growth of hepatocellular carcinoma cells. Xi bao yu fen zi mian yi xue za zhi. 31:1523–1527. 2015.In Chinese. PubMed/NCBI
9	Du R, Xia L, Sun S, Lian Z, Zou X, Gao J, Xie H, Fan R, Song J, Li X, et al: URG11 promotes gastric cancer growth and invasion by activation of beta-catenin signalling pathway. J Cell Mol Med. 14:621–635. 2010.
10	Peng W, Zhang J and Liu J: URG11 predicts poor prognosis of pancreatic cancer by enhancing epithelial-mesenchymal transition-driven invasion. Med Oncol. 31:642014. View Article : Google Scholar : PubMed/NCBI
11	Liu ZL, Wu J, Wang LX, Yang JF, Xiao GM, Sun HP and Chen YJ: Knockdown of Upregulated Gene 11 (URG11) Inhibits Proliferation, Invasion, and β-Catenin Expression in Non-Small Cell Lung Cancer Cells. Oncol Res. 24:197–204. 2016. View Article : Google Scholar
12	Pan B, Ye Y, Liu H, Zhen J, Zhou H, Li Y, Qu L, Wu Y, Zeng C and Zhong W: URG11 regulates prostate cancer cell proliferation, migration, and invasion. BioMed Res Int. 2018:40607282018. View Article : Google Scholar : PubMed/NCBI
13	Chen Y, Tan W and Wang C: Tumor-associated macrophage-derived cytokines enhance cancer stem-like characteristics through epithelial-mesenchymal transition. OncoTargets Ther. 11:3817–3826. 2018. View Article : Google Scholar
14	Yan L, Xu F and Dai CL: Relationship between epithelial-to-mesenchymal transition and the inflammatory microenvironment of hepatocellular carcinoma. J Exp Clin Cancer Res. 37:2032018. View Article : Google Scholar : PubMed/NCBI
15	Brennen WN and Isaacs JT: Mesenchymal stem cells and the embryonic reawakening theory of BPH. Nat Rev Urol. 15:703–715. 2018. View Article : Google Scholar : PubMed/NCBI
16	Usova EV, Kopantseva MR, Egorov VI, Kopantzev EP and Sverdlov ED: SNAI1 and SNAI2 - transcriptional master-regulators of epithelial-mesenchimal transition. Patol Fiziol Eksp Ter. 59:76–87. 2015.In Russian. PubMed/NCBI
17	Sung CO, Park CK and Kim SH: Classification of epithelial- mesenchymal transition phenotypes in esophageal squamous cell carcinoma is strongly associated with patient prognosis. Modern pathology: An official journal of the United States and Canadian Academy of Pathology Inc. 24:1060–1068. 2011. View Article : Google Scholar
18	Inoue T, Umezawa A, Takenaka T, Suzuki H and Okada H: The contribution of epithelial-mesenchymal transition to renal fibrosis differs among kidney disease models. Kidney Int. 87:233–238. 2015. View Article : Google Scholar
19	Lim SH, Becker TM, Chua W, Ng WL, de Souza P and Spring KJ: Circulating tumour cells and the epithelial mesenchymal transition in colorectal cancer. J Clin Pathol. 67:848–853. 2014. View Article : Google Scholar : PubMed/NCBI
20	Giles RH, van Es JH and Clevers H: Caught up in a Wnt storm: Wnt signaling in cancer. Biochim Biophys Acta. 1653:1–24. 2003.PubMed/NCBI
21	Rabbani SA, Arakelian A and Farookhi R: LRP5 knockdown: Effect on prostate cancer invasion growth and skeletal metastasis in vitro and in vivo. Cancer Med. 2:625–635. 2013.
22	Dai J, Hall CL, Escara-Wilke J, Mizokami A, Keller JM and Keller ET: Prostate cancer induces bone metastasis through Wnt-induced bone morphogenetic protein-dependent and independent mechanisms. Cancer Res. 68:5785–5794. 2008. View Article : Google Scholar : PubMed/NCBI
23	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar
24	Ferlay J, Shin HR, Bray F, Forman D, Mathers C and Parkin DM: Estimates of worldwide burden of cancer in 2008: Globocan 2008. Int J Cancer. 127:2893–2917. 2010. View Article : Google Scholar
25	Chang L, Graham PH, Hao J, Bucci J, Cozzi PJ, Kearsley JH and Li Y: Emerging roles of radioresistance in prostate cancer metastasis and radiation therapy. Cancer Metastasis Rev. 33:469–496. 2014. View Article : Google Scholar : PubMed/NCBI
26	Alberti C: Prostate cancer: Radioresistance molecular target-related markers and foreseeable modalities of radiosensitization. Eur Rev Med Pharmacol Sci. 18:2275–2282. 2014.PubMed/NCBI
27	Singh A and Settleman J: EMT, cancer stem cells and drug resistance: An emerging axis of evil in the war on cancer. Oncogene. 29:4741–4751. 2010. View Article : Google Scholar : PubMed/NCBI
28	Bronsert P, Enderle-Ammour K, Bader M, Timme S, Kuehs M, Csanadi A, Kayser G, Kohler I, Bausch D, Hoeppner J, et al: Cancer cell invasion and EMT marker expression: A three-dimensional study of the human cancer-host interface. J Pathol. 234:410–422. 2014. View Article : Google Scholar : PubMed/NCBI
29	Zhang G, Zhu F, Han G, Li Z, Yu Q, Li Z and Li J: Silencing of URG11 expression inhibits the proliferation and epithelial mesenchymal transition in benign prostatic hyperplasia cells via the RhoA/ROCK1 pathway. Mol Med Rep. 18:391–398. 2018.PubMed/NCBI
30	Du R, Huang C, Bi Q, Zhai Y, Xia L, Liu J, Sun S and Fan D: URG11 mediates hypoxia-induced epithelial-to-mesenchymal transition by modulation of E-cadherin and β-catenin. Biochem Biophys Res Commun. 391:135–141. 2010. View Article : Google Scholar
31	Gupta A, Verma A, Mishra AK, Wadhwa G, Sharma SK and Jain CK: The Wnt pathway: Emerging anticancer strategies. Recent Pat Endocr Metab Immune Drug Discov. 7:138–147. 2013. View Article : Google Scholar : PubMed/NCBI
32	Vallée A, Lecarpentier Y, Guillevin R and Vallée JN: Thermodynamics in gliomas: Interactions between the canonical WNT/beta-catenin pathway and PPAR gamma. Front Physiol. 8:3522017. View Article : Google Scholar : PubMed/NCBI
33	Tang X, Wang Y, Fan Z, Ji G, Wang M, Lin J, Huang S and Meltzer SJ: Klotho: A tumor suppressor and modulator of the Wnt/β-catenin pathway in human hepatocellular carcinoma. Lab Invest. 96:197–205. 2016. View Article : Google Scholar
34	Pandurangan AK, Divya T, Kumar K, Dineshbabu V, Velavan B and Sudhandiran G: Colorectal carcinogenesis: Insights into the cell death and signal transduction pathways: A review. World J Gastrointest Oncol. 10:244–259. 2018. View Article : Google Scholar : PubMed/NCBI
35	Li YL, Jin YF, Liu XX and Li HJ: A comprehensive analysis of Wnt/β-catenin signaling pathway-related genes and crosstalk pathways in the treatment of As2O3 in renal cancer. Ren Fail. 40:331–339. 2018. View Article : Google Scholar : PubMed/NCBI
36	Yang XZ, Cheng TT, He QJ, Lei ZY, Chi J, Tang Z, Liao QX, Zhang H, Zeng LS and Cui SZ: LINC01133 as ceRNA inhibits gastric cancer progression by sponging miR-106a-3p to regulate APC expression and the Wnt/β-catenin pathway. Mol Cancer. 17:1262018. View Article : Google Scholar
37	Adebayo Michael AO, Ko S, Tao J, Moghe A, Yang H, Xu M, Russell JO, Pradhan-Sundd T, Liu S, Singh S, et al: Inhibiting glutamine-dependent mTORC1 activation ameliorates Liver cancers driven by β-catenin mutations. Cell Metab: Jan. 28:2019Epub ahead of print.
38	Ren W, Wang D, Li C, Shu T, Zhang W and Fu X: Capn4 expression is modulated by microRNA-520b and exerts an oncogenic role in prostate cancer cells by promoting Wnt/beta-catenin signaling. Biomed Pharmacother. 108:467–475. 2018. View Article : Google Scholar : PubMed/NCBI
39	Zhang Z, Cheng L, Li J, Farah E, Atallah NM, Pascuzzi PE, Gupta S and Liu X: Inhibition of the Wnt/β-catenin pathway overcomes resistance to enzalutamide in castration-resistant prostate cancer. Cancer Res. 78:3147–3162. 2018.PubMed/NCBI
40	Sha J, Han Q, Chi C, Zhu Y, Pan J, Dong B, Huang Y, Xia W and Xue W: PRKAR2B promotes prostate cancer metastasis by activating Wnt/β-catenin and inducing epithelial-mesenchymal transition. J Cell Biochem. 119:7319–7327. 2018. View Article : Google Scholar : PubMed/NCBI